Introduction
As a student studying medical assisting, I am fascinated by advancements in cardiovascular technology, particularly artificial hearts, which offer life-saving options for patients with end-stage heart failure. This essay explores the functionality of artificial hearts by drawing on research from three credible sources: the British Heart Foundation (BHF), the National Health Service (NHS), and a peer-reviewed article from the New England Journal of Medicine. The purpose is to compare the human heart with artificial alternatives, address key inquiries about their structures and functions, and evaluate recipient criteria. This discussion incorporates my perspective from clinical placement experiences, where I observed patients with heart conditions, highlighting the real-world implications of such devices. Key points include structural analogies, functional differences, and eligibility requirements, ultimately underscoring the balance between innovation and ethical considerations in medical assisting.
Comparison of Human and Artificial Heart Structures and Functions
The human heart is a muscular organ comprising four chambers—two atria and two ventricles—that pump blood through rhythmic contractions, ensuring oxygenated blood circulates via the pulmonary and systemic circuits (British Heart Foundation, 2023). In contrast, an artificial heart, such as the SynCardia Total Artificial Heart, is a mechanical device that replaces the native heart entirely, using pneumatic pumps to mimic blood flow (Copeland et al., 2004). While the human heart relies on biological tissues and electrical impulses from the sinoatrial node for autonomous beating, artificial hearts depend on external power sources and controllers, making them more susceptible to mechanical failure but capable of sustaining life in severe cases.
Addressing specific inquiries, first, human heart structures analogous to those in artificial hearts include the ventricles, which are replicated by the device’s pumping chambers that eject blood similarly to natural ventricular contraction (NHS, 2023). Indeed, the artificial heart’s valves mirror the human aortic and pulmonary valves, preventing backflow and ensuring unidirectional circulation. Furthermore, the atria-like inflow ports in artificial hearts connect to the body’s veins, facilitating blood entry much like the natural atria.
Secondly, primary functional differences lie in adaptability and endurance. The human heart adjusts its rate and force based on physiological needs, such as during exercise, through autonomic nervous system regulation (British Heart Foundation, 2023). Artificial hearts, however, operate at fixed rates set by external drivers, lacking this innate responsiveness, which can lead to complications like thromboembolism (Copeland et al., 2004). These differences impact oxygenated blood availability; for instance, the artificial heart’s inability to dynamically increase output may result in inadequate perfusion during high-demand activities, potentially causing tissue hypoxia. In my placement experience assisting with cardiac monitoring, I saw how natural hearts compensate effortlessly, whereas mechanical alternatives require constant medical oversight, arguably limiting patient independence.
Although not fully addressing all inquiries, it is worth noting that the artificial heart interconnects with four key cardiovascular structures: the superior and inferior vena cava (for venous return), the pulmonary artery (for lung oxygenation), the aorta (for systemic distribution), and indirectly the pulmonary veins via surgical adaptation (NHS, 2023). This integration, while effective, highlights the device’s role as a bridge to transplantation rather than a permanent solution.
Evaluation of Recipient Criteria
To qualify for an artificial heart, patients typically must have end-stage biventricular heart failure unresponsive to other treatments, be in good overall health excluding the heart (e.g., no active infections or malignancies), and demonstrate psychological readiness for the device’s demands (Copeland et al., 2004; NHS, 2023). Additional criteria include age (often under 75) and a commitment to post-implant care, such as anticoagulation therapy (British Heart Foundation, 2023).
I generally agree with these requirements, as they ensure the procedure’s benefits outweigh risks; for example, excluding those with comorbidities prevents futile interventions, aligning with ethical principles in medical assisting. However, I propose adding a prerequisite for comprehensive family support assessment, given the device’s external components require ongoing assistance—drawing from my experience where family involvement improved patient outcomes in similar scenarios. Conversely, I suggest removing strict age limits, as they may discriminate against otherwise fit older adults; advancements in technology could make artificial hearts viable for a broader range, promoting equity. My reasoning stems from a critical view that criteria should evolve with evidence, balancing resource allocation and patient quality of life.
Conclusion
In summary, artificial hearts replicate key human heart structures like ventricles and valves but differ functionally in adaptability, affecting oxygenated blood supply and necessitating careful recipient selection. These insights, informed by credible sources and personal observations, emphasise the device’s value as a temporary measure while highlighting areas for improvement in criteria to enhance accessibility. Ultimately, as medical assisting evolves, such technologies underscore the need for holistic patient care, with implications for reducing transplant wait times and improving survival rates in heart failure cases.
References
- British Heart Foundation. (2023) Heart failure. British Heart Foundation.
- Copeland, J.G., Smith, R.G., Arabia, F.A., Nolan, P.E., Sethi, G.K., Slepian, M.J., McCarthy, M., Silver, M., Tsau, P.H. and Paramesh, V. (2004) Cardiac replacement with a total artificial heart as a bridge to transplantation. New England Journal of Medicine, 351(9), pp.859-867.
- NHS. (2023) Heart failure – Treatment. National Health Service.
